Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy – results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing
Authors:
J. Krejčí 1; L. Groch 1; J. Meluzín 1; T. Vykypěl 1; J. Halámek 2; J. Vítovec 1
Authors‘ workplace:
I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta prof. MUDr. J. Vítovec, CSc.
1; Ústav přístrojové techniky České akademie věd, Brno, ředitel RNDr. L. Frank, DrSc.
2
Published in:
Vnitř Lék 2006; 52(4): 313-320
Category:
Original Contributions
Overview
Background:
Percutaneous transluminal septal myocardial ablation (PTSMA) and pacemaker (PM) therapy with apical preexcitation are therapeutic options for hypertrophic obstructive cardiomyopathy (HOCM) patients with symptoms despite pharmacological therapy. Aim: evaluation and comparison of treatment results of PTSMA and PM implantation.
Patients:
22 HOCM patients (NYHA class III and IV) with left ventricle outflow tract gradient (LVOTG) at rest more than 30 mm Hg. In group A were evaluated 11 patients treated by PTSMA. Left ventricle outflow tract gradient (LVOTG) was 90.5 ± 16.0 mm Hg, NYHA class 3.1 ± 0.2. Group B included 11 patients treated by dual chamber PM implantation, LVOTG in this group was 105 ± 48 mm Hg, NYHA class 3.0 ± 0.4.
Results:
NYHA class in the group A decreased after treatment to 1.8 ± 0.6 (p < 0.01), LVOTG to 24 ± 12 mm Hg (p < 0.001). There was observed significant decrease in grade of systolic anterior motion (SAM), interventricular septum (IVS) thickness and left atrium (LA) size. Left ventricle end systolic diameter (LV SD) and left ventricle end diastolic diameter (LV DD) increased during follow-up. Decrease of NYHA class in the group B was to 2.1 ± 0.6 (p < 0.001), LVOTG to 25.5 ± 21.0 mm Hg (p < 0.001). Changes of other parameters in the group B were not significant, except decrease of SAM.
Comparison of both groups:
NYHA class change PTSMA/PM: 1.3 ± 0.6/0.9 ± 0.4 (p < 0.05), LVOTG change PTSMA/PM: -66 ± 20/-79 ± 46 mm Hg (p = n.s.). LV SD assessment - comparison of LV SD change PTSMA/PM: 5 ± 5/1 ± 5 mm (p < 0.05). LA assessment - comparison of LA change PTSMA/PM: -5 ± 5/-1 ± 4 mm (p < 0.05). Other changes were not significant.
Conclusion:
Both therapeutic approaches - PTSMA and PM implantation - resulted in significant improvement of functional capacity assessed by NYHA classification. Decrease of LVOTG was also significant and was similar in both groups, NYHA class improvement as well as LA size decrease and LV DS increase were more expressed in PTSMA group.
Key words:
hypertrophic obstructive cardiomyopathy - percutaneous transluminal septal myocardial ablation - pacemaker therapy
Sources
1. Braunwald E. Hypertrophic Cardiomyopathy. The benefits of a multidisciplinary approach. N Engl J Med 2002; 347: 1306-1307.
2. Fananapazir L, McAreavey D. Therapeutic option in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 1998; 31: 259-264.
3. Firoozi S, Elliott P, Sharma S et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodymic and exercice outcomes. Eur Heart J 2002; 23: 1617.
4. Gadler F. Pacing in hypertrophic cardiomyopathy. Eur Heart J 2001; 3(Suppl): L32-L37.
5. Gregor P. Hypertrofická kardiomyopatie. Praha: Scientia Medica 1992.
6. Kappenberger L, Linde C, Daugbert C et al. Pacing in hypertrophic cardiomyopathy. A randomized crossover study. PIC study group. Eur Heart J 1997; 18: 1249-1256.
7. Krejčí J. Současný pohled na hypertrofickou kardiomyopatii. Cor Vasa 2003; 45: 507-512.
8. Maron BJ. Hypertrophic cardiomyopathy. JAMA 2002; 287: 1308-1320.
9. Maron BJ, McKenna WJ, Danielson GK et al. ACC/ESC Clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J 2003; 24: 1965-1991.
10. Maron BJ, Nishimura RA, McKenna WJ et al. Assesment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: 2927-2933.
11. Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
12. McKenna WJ, Sharma S, Elliott PM. Management strategies in hypertrophic cardiomyopathy: influence of age and morphology. Eur Heart Suppl. 2001; 3(Suppl L): L10-L14.
13. Mohiddin S, Rowe G, Hathaway L et al. Comparison of novel strategy therapies for obstructive hypertrophic cardiomyopathy: Relation of relief of left ventricular outflouw obstruction to improved symptoms and health-related quality of life parameters. J Am Coll Cardiol 2003; 41(Suppl A): 145A.
14. Morrow AG, Brockenbrough EC. Surgical treatment of IHSS. Technic and hemodynamic results of ventriculotomy. Ann Surg 1961; 154: 181-189.
15. Nagueh SF, Ommen SR, Lakkis NM et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-1706.
16. Novák M, Kamarýt P, Toman J et al. Léčení hypertrofické obstrukční kardiomyopatie síněmi spouštěnou stimulací komor s umělou preexcitací. Scripta Medica 1995; 68: 363-364.
17. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, Part I. Circulation 2001; 104: 2113-2116.
18. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, Part II. Circulation 2001; 104: 2249-2252.
19. Ruzyllo W, Chojnowska L, Demkow M et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercice capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000; 21: 770-777.
20. Ryden L, Gadler F. Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success? Eur Heart Suppl. 2001; 3(Suppl L): L21-L25.
21. Seggewiss H. Medical therapy versus interventional therapy in hypertrophic obstructive cardiomyopathy. Curr Control Trials Cardiovasc Med 2000; 1: 115-119.
22. Shamim W, Yousufuddin M, Wang D et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002; 347: 1326-1333.
23. Schulte HD, Gramsch-Zabel H, Schwartzkopff B et al. Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy (in German). Z Kardiol 1999; 88: 163-172.
24. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214.
25. Slade AK, Sadoul N, Shapiro L et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart 1996; 75: 44-49.
26. Spirito P, Seidman CE, McKenna WJ et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
27. Veselka J, Tesař D, Páleníčková J et al. Katetrizační léčba hypertrofické obstrukční kardiomyopatie. Cor Vasa 2003; 45: 80-84.
28. Wigle ED, Rakowski H, Kimball BP et al. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995; 92: 1680-1692.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2006 Issue 4
Most read in this issue
- Medical videothoracoscopy in diagnosis and therapy of pleural effusions
- Primary prevention of ischemic heart disease in middle-aged men living in Prague: Results of twenty-year research
- The Prophylaxis against Venous Thromboembolic Complications in Internal Medicine - the Gap between Theory and Practice
- Ubiquitins, proteasomes, sumoylation and application today and in future for cancer and other diseases therapy I. Ubiquitin-proteasome system and the transcription factor NF-κB